AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer
By Sasha Stanton, MD, PhD
Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next
By Paul Shaughnessy, MD
Before CAR-T cell therapy existed, patients with chemotherapy-refractory diffuse large B-cell lymphoma had a median overall survival of 6.3 months, a complete response rate of 7%, and only 20% alive at two years.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment
By Allan Pereira, MD, PhD
Gastroesophageal cancers (encompassing adenocarcinomas and squamous cell carcinomas of the esophagus and stomach, including gastroesophageal junction tumors) have seen more treatment advances in the past two years than in the preceding decade.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia
By Dr. Ronan Hsieh
Upper GI cancers remain among the most lethal malignancies worldwide, and the treatment landscape has been evolving rapidly since the approvals of trastuzumab in HER2-positive disease and checkpoint inhibitors across the HER2-negative population.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer
By Rachael A. Safyan, MD
ASCO 2026 brought two late-breaking presentations that are reshaping the treatment of hepatocellular carcinoma and pancreatic cancer.
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan
By Stacey A. Cohen, MD
Before discussing any of the specific advances from ASCO 2026, the single most important principle in colorectal cancer is straightforward: test all patients for microsatellite instability (MSI).
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives
By Alexandra Sokolova, MD
ASCO 2026 brought multiple practice-influencing trials in prostate cancer spanning localized high-risk disease, metastatic hormone-sensitive disease, and de-escalation for exceptional responders.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
While ide-cel and cilta-cel are generally considered safe and have remarkable therapeutic impact for relapsed/refractory myeloma, both agents carry a broad and clinically significant toxicity burden that practitioners must recognize and actively surveil.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist
By Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD
Ide-cel was the first anti-BCMA CAR-T product approved by the FDA in March 2021, employing a single anti-BCMA single-chain variable fragment.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.
Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results
By Krutika Gohil, MD
Results of the RASolute 302 clinical trial show Daraxonrasib nearly doubles survival with fewer side effects compared to chemotherapy for pancreatic cancer patients.